Revolution Medicines Inc
NASDAQ:RVMD
Income Statement
Earnings Waterfall
Revolution Medicines Inc
Income Statement
Revolution Medicines Inc
| Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
0
|
|
| Revenue |
48
N/A
|
50
+4%
|
48
-3%
|
46
-5%
|
46
+0%
|
43
-7%
|
42
-3%
|
40
-3%
|
29
-29%
|
29
+2%
|
27
-9%
|
27
+2%
|
30
+8%
|
35
+20%
|
35
-2%
|
30
-15%
|
26
-11%
|
12
-56%
|
5
-61%
|
1
-84%
|
1
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||
| Operating Expenses |
(95)
|
(104)
|
(113)
|
(128)
|
(143)
|
(154)
|
(169)
|
(184)
|
(198)
|
(217)
|
(235)
|
(253)
|
(279)
|
(294)
|
(310)
|
(352)
|
(395)
|
(499)
|
(557)
|
(601)
|
(657)
|
(690)
|
(657)
|
(796)
|
(1 182)
|
|
| Selling, General & Administrative |
(12)
|
(12)
|
(15)
|
(18)
|
(20)
|
(21)
|
(23)
|
(25)
|
(28)
|
(30)
|
(33)
|
(36)
|
(38)
|
(41)
|
(45)
|
(49)
|
(54)
|
(76)
|
(85)
|
(92)
|
(101)
|
(97)
|
(93)
|
(122)
|
(195)
|
|
| Research & Development |
(82)
|
(92)
|
(98)
|
(111)
|
(123)
|
(132)
|
(146)
|
(159)
|
(170)
|
(187)
|
(203)
|
(218)
|
(241)
|
(253)
|
(266)
|
(303)
|
(341)
|
(423)
|
(472)
|
(509)
|
(553)
|
(592)
|
(564)
|
(675)
|
(987)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(46)
N/A
|
(54)
-17%
|
(65)
-20%
|
(82)
-27%
|
(96)
-17%
|
(111)
-15%
|
(127)
-15%
|
(144)
-13%
|
(169)
-18%
|
(188)
-11%
|
(209)
-11%
|
(226)
-8%
|
(249)
-10%
|
(258)
-4%
|
(275)
-7%
|
(322)
-17%
|
(369)
-15%
|
(487)
-32%
|
(553)
-13%
|
(601)
-9%
|
(656)
-9%
|
(690)
-5%
|
(657)
+5%
|
(796)
-21%
|
(1 182)
-48%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||
| Interest Income Expense |
2
|
2
|
3
|
3
|
3
|
2
|
2
|
1
|
1
|
1
|
1
|
2
|
4
|
9
|
16
|
26
|
34
|
47
|
64
|
75
|
84
|
87
|
64
|
54
|
66
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
6
|
5
|
2
|
(7)
|
(6)
|
(15)
|
|
| Pre-Tax Income |
(44)
N/A
|
(52)
-17%
|
(62)
-19%
|
(79)
-28%
|
(94)
-18%
|
(109)
-16%
|
(126)
-16%
|
(143)
-14%
|
(168)
-18%
|
(187)
-11%
|
(208)
-11%
|
(224)
-8%
|
(245)
-9%
|
(249)
-2%
|
(260)
-4%
|
(297)
-14%
|
(335)
-13%
|
(440)
-31%
|
(488)
-11%
|
(523)
-7%
|
(567)
-8%
|
(601)
-6%
|
(599)
+0%
|
(748)
-25%
|
(1 131)
-51%
|
|
| Net Income | ||||||||||||||||||||||||||
| Tax Provision |
0
|
4
|
5
|
5
|
5
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
4
|
(0)
|
1
|
1
|
1
|
0
|
|
| Income from Continuing Operations |
(44)
|
(48)
|
(57)
|
(74)
|
(89)
|
(108)
|
(126)
|
(143)
|
(169)
|
(187)
|
(208)
|
(224)
|
(245)
|
(249)
|
(259)
|
(296)
|
(331)
|
(436)
|
(484)
|
(519)
|
(567)
|
(600)
|
(599)
|
(748)
|
(1 131)
|
|
| Net Income (Common) |
(57)
N/A
|
(62)
-9%
|
(71)
-14%
|
(85)
-20%
|
(95)
-12%
|
(110)
-16%
|
(126)
-14%
|
(143)
-14%
|
(169)
-18%
|
(187)
-11%
|
(208)
-11%
|
(224)
-8%
|
(245)
-9%
|
(249)
-2%
|
(259)
-4%
|
(296)
-14%
|
(331)
-12%
|
(436)
-32%
|
(484)
-11%
|
(519)
-7%
|
(567)
-9%
|
(600)
-6%
|
(599)
+0%
|
(748)
-25%
|
(1 131)
-51%
|
|
| EPS (Diluted) |
-1.39
N/A
|
-1.05
+24%
|
-1.2
-14%
|
-1.44
-20%
|
-1.46
-1%
|
-2.01
-38%
|
-1.78
+11%
|
-1.94
-9%
|
-2.29
-18%
|
-2.57
-12%
|
-2.81
-9%
|
-3.03
-8%
|
-2.89
+5%
|
-3.08
-7%
|
-2.73
+11%
|
-2.77
-1%
|
-3.03
-9%
|
-3.86
-27%
|
-2.93
+24%
|
-3.14
-7%
|
-3.39
-8%
|
-3.58
-6%
|
-3.17
+11%
|
-3.95
-25%
|
-5.95
-51%
|
|